お知らせ • Mar 31
SCYNEXIS, Inc. announced that it expects to receive $40.019125 million in funding from Squadron Capital Management Llc, Propel Bio Partners LLC, Great Point Partners, LLC, Adage Capital Management, L.P.
SCYNEXIS, Inc. entered into a Securities Purchase Agreement and announced a private placement of (i) 34,750,000 Common Shares of the company, par value $0.001 per share (ii) pre-funded warrants to purchase up to 8,750,000 shares of Common Stock and (iii) accompanying common warrants to purchase up to an aggregate of 43,500,000 shares of Common Stock or Pre-Funded Warrants for aggregate gross proceeds of $40,000,000 on March 30, 2026. The transaction involves participation from new investor Great Point Partners, LLC, Squadron Capital Management LLC, Adage Capital Management, L.P., Propel Bio Partners, a large healthcare-dedicated fund, and other investors. Each Share or Pre-Funded Warrant will be accompanied by one Common Warrant. The 34,750,000 Common Shares and accompanying Common Warrants were sold at a combined price of $0.92 per Share and accompanying Common Warrant, and the 8,750,000 Pre-Funded Warrants and accompanying Common Warrants were sold at a combined price of $0.9199 per Pre-Funded Warrant and accompanying Common Warrant. The aggregate share issuance includes 108,695 Shares and accompanying Common Warrants that were sold to the Company’s President and Chief Executive Officer, David Angulo. Each Pre-Funded Warrant has an initial exercise price per share of $0.0001, subject to certain adjustments. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until the Pre-Funded Warrants are exercised in full. Each Common Warrant is exercisable for one Share at an exercise price of $1.20 per Share, or one Pre-Funded Warrant at an exercise price of $0.0001 per Pre-Funded Warrant in lieu thereof. The Common Warrants will be exercisable beginning on the effective date of the stockholder approval relating to the proposed increase in the Company’s authorized shares of Common Stock and will expire on 5:00 p.m. (New York City time) on the earlier of (i) the fifth (5th) anniversary of its original issue date and (ii) the thirtieth (30th) day after the Company publicly releases topline data at Week 48 from the Company’s Phase 2 proof-of-concept clinical study. In connection with the private placement, the Company has agreed to convene a stockholder meeting no later than 90 days following the closing of the private placement to seek the shareholders approval. Under the terms of the Pre-Funded Warrants, the Company may not affect the exercise of any Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Pre-Funded Warrant. The Company estimates that the gross proceeds to the Company from the private placement will be approximately $40,000,000, before deducting placement agent fees and transaction-related expenses, and up to an additional $52,200,000 in gross proceeds if the Warrants are fully exercised for cash, subject to the shareholder approval. The company entered into a Registration Rights Agreement with the investors, under which the Company must file a registration statement with the SEC within 30 days of closing to allow resale of the private placement securities, and use best efforts to have it effective as soon as possible, but no later than 75 days after filing, and maintain effectiveness until the securities can be sold freely under Rule 144 or have been sold. The agreement also covers customary fees, expenses, and indemnification. The securities being issued in this transaction are restricted on transfer. The transaction is carried out pursuant to Regulation D. The Company has agreed to pay the placement agent customary placement fees in its capacity as placement agent for the sale of the Shares and the Warrants to the Investors. The private placement is expected to close on or about April 1, 2026, subject to the satisfaction of customary closing conditions.